Skip to main content
Erschienen in: Journal of General Internal Medicine 11/2013

01.11.2013 | Review Article

Midodrine for Orthostatic Hypotension: A Systematic Review and Meta-Analysis of Clinical Trials

verfasst von: Ajay K. Parsaik, MD, Balwinder Singh, MD, Osama Altayar, MD, Soniya S. Mascarenhas, RN, Shannon K. Singh, Patricia J. Erwin, M. Hassan Murad, MD, MPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

ABSTRACT

OBJECTIVE

To perform a systematic review and meta-analysis of clinical trials evaluating the efficacy and safety of midodrine in orthostatic hypotension (OH).

METHODS

We searched major databases and related conference proceedings through June 30, 2012. Two reviewers independently selected studies and extracted data. Random-effects meta-analysis was used to pool the outcome measures across studies.

RESULTS

Seven trials were included in the efficacy analysis (enrolling 325 patients, mean age 53 years) and two additional trials were included in the safety analysis. Compared to placebo, the mean change in systolic blood pressure was 4.9 mmHg (p = 0.65) and the mean change in mean arterial pressure from supine to standing was −1.7 mmHg (p = 0.45). The change in standing systolic blood pressure before and after giving midodrine was 21.5 mmHg (p < 0.001). A significant improvement was seen in patients’ and investigators’ global assessment symptoms scale (a mean difference of 0.70 [95 % CI 0.30–1.09; p < 0.001] and 0.80 [95 % CI 0.76–0.85; p < 0.001], respectively). There was a significant increase in risk of piloerection, scalp pruritis, urinary hesitancy/retention, supine hypertension and scalp paresthesia after giving midodrine. The quality of evidence was limited by imprecision, heterogeneity and increased risk of bias.

CONCLUSION

There is insufficient and low quality evidence to support the use of midodrine for OH.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161:46–8.PubMedCrossRef Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161:46–8.PubMedCrossRef
2.
Zurück zum Zitat Low PA. Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction. Neurology. 1995;45:S4–5.PubMedCrossRef Low PA. Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction. Neurology. 1995;45:S4–5.PubMedCrossRef
3.
Zurück zum Zitat Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7:451–8.PubMedCrossRef Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7:451–8.PubMedCrossRef
5.
Zurück zum Zitat Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA. 2010;304:2172–3.PubMedCrossRef Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA. 2010;304:2172–3.PubMedCrossRef
6.
Zurück zum Zitat Mitka M. FDA takes slow road toward withdrawal of drug approved with fast-track process. JAMA. 2011;305:982–4.PubMedCrossRef Mitka M. FDA takes slow road toward withdrawal of drug approved with fast-track process. JAMA. 2011;305:982–4.PubMedCrossRef
7.
Zurück zum Zitat Mitka M. Trials to address efficacy of midodrine 18 years after it gains FDA approval. JAMA. 2012;307:1124–7.PubMedCrossRef Mitka M. Trials to address efficacy of midodrine 18 years after it gains FDA approval. JAMA. 2012;307:1124–7.PubMedCrossRef
9.
Zurück zum Zitat Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46.
10.
Zurück zum Zitat Higgins JP, Green S, Eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011. Higgins JP, Green S, Eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.​cochrane-handbook.​org 2011.
11.
Zurück zum Zitat Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.PubMedCrossRef Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.PubMedCrossRef
12.
Zurück zum Zitat Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.PubMedCrossRef Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.PubMedCrossRef
13.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
14.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
15.
Zurück zum Zitat Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99:604–10.PubMedCrossRef Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99:604–10.PubMedCrossRef
16.
Zurück zum Zitat Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95:38–48.PubMedCrossRef Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95:38–48.PubMedCrossRef
17.
Zurück zum Zitat Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs. placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277:1046–51.PubMedCrossRef Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs. placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277:1046–51.PubMedCrossRef
18.
Zurück zum Zitat Schrage WG, Eisenach JH, Dinenno FA, et al. Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure. J Appl Physiol. 2004;97:1978–84.PubMedCrossRef Schrage WG, Eisenach JH, Dinenno FA, et al. Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure. J Appl Physiol. 2004;97:1978–84.PubMedCrossRef
19.
Zurück zum Zitat Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M, Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil. 2010;91:1429–35.PubMedCrossRef Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M, Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil. 2010;91:1429–35.PubMedCrossRef
20.
Zurück zum Zitat Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120–4.PubMedCrossRef Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120–4.PubMedCrossRef
21.
Zurück zum Zitat Axelrod FB, Krey L, Glickstein JS, Weider Allison J, Friedman D. Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia. J Auton Nerv Syst. 1995;55:29–35.PubMedCrossRef Axelrod FB, Krey L, Glickstein JS, Weider Allison J, Friedman D. Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia. J Auton Nerv Syst. 1995;55:29–35.PubMedCrossRef
22.
Zurück zum Zitat Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab. 1998;83:339–43.PubMedCrossRef Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab. 1998;83:339–43.PubMedCrossRef
23.
Zurück zum Zitat Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology. 1988;38:951–6.PubMedCrossRef Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology. 1988;38:951–6.PubMedCrossRef
24.
Zurück zum Zitat Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41:587–94.PubMedCrossRef Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41:587–94.PubMedCrossRef
25.
Zurück zum Zitat Pathak A, Raoul V, Montastruc JL, Senard JM. Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol. 2005;61:471–4.PubMedCrossRef Pathak A, Raoul V, Montastruc JL, Senard JM. Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol. 2005;61:471–4.PubMedCrossRef
26.
Zurück zum Zitat Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–29.PubMedCrossRef Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–29.PubMedCrossRef
Metadaten
Titel
Midodrine for Orthostatic Hypotension: A Systematic Review and Meta-Analysis of Clinical Trials
verfasst von
Ajay K. Parsaik, MD
Balwinder Singh, MD
Osama Altayar, MD
Soniya S. Mascarenhas, RN
Shannon K. Singh
Patricia J. Erwin
M. Hassan Murad, MD, MPH
Publikationsdatum
01.11.2013
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 11/2013
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2520-3

Weitere Artikel der Ausgabe 11/2013

Journal of General Internal Medicine 11/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.